NCT02933528View on ClinicalTrials.gov

Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 11, 2016

Primary Completion Date

August 11, 2017

Study Completion Date

November 27, 2017

Conditions
Psoriasis
Interventions
DRUG

DSXS Topical product

once daily for 28 days

Trial Locations (1)

10532

Taro Pharmaceuticals USA, Inc., Hawthorne

All Listed Sponsors
lead

Sun Pharmaceutical Industries, Inc.

INDUSTRY

NCT02933528 - Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS | Biotech Hunter | Biotech Hunter